



24 March 2025

**ReNeuron Group plc
("ReNeuron" or the "Company")**

Exit from Administration as a Going Concern

Re-launch as a Private company focused on its stem cell line development expertise

Re-structured Board & Management Team

ReNeuron Group plc, which has developed a proprietary stem cell-derived, exosome-based, drug delivery platform, announces that on 17th March 2025 the Company's administrators Cork Gully ("The Administrators") filed the relevant court documents to confirm that "the purpose of administration has been sufficiently achieved" and notice of the end of administration was filed with the court and the registrar of companies.

Iain Ross, Chairman, commented:

"During Administration, with the support and encouragement of the Administrators, Randolph Corteling, our Chief Scientific Officer, and I have explored the opportunity to re-launch and re-position ReNeuron as a private biotech company focused on its stem cell line development expertise, IP and know-how.

"I confirm that the Company has exited administration as a 'going concern' and has sufficient working capital to support its operations for a minimum of 12 months and has already identified a number immediate licence and fee generating opportunities.

"In addition, I am very pleased to announce that Randolph Corteling has been appointed as Managing Director and will lead the Company through its next phase of development. The ReNeuron Board will comprise myself as Chairman, with Barbara Staehelin remaining as Non-Executive Director and Chair of the Audit & Risk Committee and Randolph as Managing Director. Non-Executive Directors Michael Owen and Martin Walton have stood down from the Board effective today and I want to thank them not only for their unstinting support over the last few years but also for their support and wise counsel during the administration process.

"Finally, as the Company is no longer a publicly listed company, I confirm our intention is to work closely with our existing shareholders to determine the best outcome for them including exploring options to allow shareholders to trade shares privately. Further details will be communicated in due course."

To register to receive ongoing investor communications from ReNeuron please email: lifesciences@walbrookpr.com

Randolph Corteling, Managing Director and Chief Scientific Officer, commented:

"I am very excited to take on this new challenge as I have always believed ReNeuron has a significant untapped potential to generate an income revenue stream by making available through licences and collaborations a proportion of its' portfolio of established stem cell lines for research and development purposes, whilst continuing to work in collaboration with third parties to address and overcome their drug delivery challenges by utilising ReNeuron's proprietary exosomes-based drug delivery platform - CustomEX™.

"Our vision is to exploit the CustomEX™ platform to enable the targeted delivery of advanced therapeutic modalities such as siRNA, mRNA and gene editing complexes and to develop the next generation of gene therapies, in partnership with biotech or big pharma, for previously untreatable disease of the CNS, lung and liver. This will be facilitated by the out-licensing of our unique stem cell lines to create a cost-effective and self-sustaining R&D business".

BACKGROUND

Appointment of Administrators

On 20 March 2024, ReNeuron Group Plc was placed into administration along with its UK subsidiaries: ReNeuron Holdings Limited, ReNeuron Limited and ReNeuron (UK) Limited (together "the Group"). Mark Smith and Stephen Cork of Cork Gully LLP were appointed to act as Joint Administrators. The affairs, business and property of the Group were managed by the Joint Administrators from that date.

Cancellation from AIM

Pursuant to Rule 41 of the AIM Rules, and with the ordinary shares of the Company having been suspended for more than six months, the Company's admission to trading on AIM was cancelled with effect from 7.00 a.m. on 2 September 2024

("Cancellation"). Upon the Cancellation becoming effective, Allenby Capital ceased to be nominated adviser to the Company pursuant to the AIM Rules.

Takeover Code

The Company remains subject to the Takeover Code for a period of at least ten years following the Cancellation from AIM, provided the Company continues to have its place of central management and control in the UK, Channel Islands or Isle of Man. However, in the event that, subsequent to the Cancellation further Board changes result in the Company's place of central management and control being outside the UK, Channel Islands or Isle of Man, then the Company may not be subject to the Takeover Code.

It should be noted that the future scope of the application of the Takeover Code is currently under review by the Panel and is the subject matter of a public consultation paper (PCP 2024/1) which proposes a refocusing and significant narrowing of the types of companies that are subject to the Takeover Code. This public consultation closed on 31 July 2024. If these rule changes are adopted in the form and broadly in the timescale proposed, the Company would cease to be subject to the Takeover Code three years after the date of implementation of such changes.

Enquiries:

ReNeuron Group plc

Iain Ross, Chairman
Randolph Corteling, Managing Director & Chief Scientific Officer

Via Walbrook PR

Walbrook PR (Media & Investor Relations)

Alice Woodings
Paul McManus

Tel: +44 (0)20 7933 870 lifesciences@walbrookpr.com

Mob: +44 (0)7407 804 654

Mob: +44 (0)7980 541 893